Mezigdomide
As of the edition of 20 October 2026, Mezigdomide is a small molecule: in active development; acts on CRBN.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 28, 3 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CRBN | Protein cereblon | Q96SW2 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 15 | 7 | 7 | 1 |
| Phase 2 | 10 | 0 | 8 | 2 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 28 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Karyopharm Therapeutics | Lead sponsor of trials | 2015 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2018 to now |
| K36 Therapeutics | Lead sponsor of trials | 2023 to now |
| AbbVie | Lead sponsor of trials | 2025 to now |